Phase 2 N=25 Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma
Glioblastoma · Astrocytoma · Oligodendroglioma
Primary: Progression-free Survival at 6-months — 17.3 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=36 Non-Interventional Study Of Indian Patients With Advanced Renal Cell Cancer Receiving Therapy With Sutent
Renal Cell Carcinoma
Primary: Progression Free Survival (PFS)
Phase 2 N=14 Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
Leukemia
Primary: Dose-limiting Toxicity — 0; 0 participants
N/A N=507 Study Evaluating Changes In Mammographic Breast Density
Osteoporosis
Primary: Percent Change From Baseline in Mammographic Breast Density at Month 24 — -0.39; -0.05; -0.23; -0.42 percent change
N/A N=110 Re-licensing Study to Assess Virosomal Influenza Vaccine Formulated With WHO Recommended Influenza Strains
Influenza
Primary: Seroprotection — 94.5; 100; 100; 100 percentage of subjects
Phase 3 N=110 Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains
Influenza
Primary: Seroprotection — 65.5; 80.0; 98.2; 98.2 percentage of subjects
Phase 3 N=382 Long-Acting Injectable Risperidone in the Treatment of Schizophrenia
Schizoaffective Disorder · Schizophrenia
Primary: Hospitalization-free Survival - Time to Event — NA; 1.97 years — p=0.39
N/A N=200 Clinical Evaluation of Two Toric Contact Lenses in Current Non-toric Lens Users
Astigmatism
Primary: Overall Success in Fitting With a Toric Contact Lens — 80; 74; 70 percentage of participants
Phase 2 N=594 Improving Treatment Adherence in HIV-Infected Individuals
HIV Antiretroviral Therapy (ART) Adherence · Health Behavior
Primary: AIDS Clinical Trials Group (ACTG) 3-day Recall Measure of Doses Taken — 72.89; 75.46; 74.86; 77.33 percent with 100% adherence — p=0.12
Phase 2 N=120 Therapeutic Exploratory Study of Comparing Natamycin and Voriconazole to Treat Fungal Corneal Ulcer
Fungal Keratitis
Primary: Best Spectacle Corrected Visual Acuity (BSCVA) 3 Months After Enrollment, Adjusting for Enrollment BSCVA in a Multiple Linear Regression Model — 0.61; 0.71 logMAR — p=0.29
N/A N=30 The Effect of Interscalene Peripheral Nerve Block With 0.25% Bupivacaine vs 0.125% Bupivacaine on Lung Function
Diaphragm Paralysis
Primary: Abnormal Lung Function — 11; 3 participants w/ abnormal diaphragm fxn
Phase 2 N=61 Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer
Primary Peritoneal Cavity Cancer · Recurrent Ovarian Epithelial Cancer
Primary: Tumor Response — 7; 30; 12; 6 participants
Phase 3 N=748 A Study of the Effectiveness and Safety of Mometasone Furoate Nasal Spray (MFNS, SCH 032088) for the Treatment of Nasal Polyps (P05604)
Nasal Polyps
Primary: Change From Baseline in Congestion/Obstruction Score — -0.56; -0.42 score on a scale — p=0.0007
N/A N=64 Enhancing Conservative Treatment for Urge Incontinence
Urinary Incontinence
Primary: Change in Incontinent Episodes Immediately Post-treatment — -88.5; -78.3 percentage change — p=.16
Phase 1 N=24 Investigation of Ritonavir Effects on Afatinib Exposure in Healthy Subjects
Healthy
Primary: Area Under Curve From 0 to tz (AUC0-tz) — 392; 478; 438 ng*h/mL — p=0.1009